UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis

RegulatoryapprovedZILBRYSQPositive

AI Analysis

Summary

UCB announced FDA approval of an autoinjector for self-administration of ZILBRYSQ (zilucoplan) in adults with generalized myasthenia gravis. ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily subcutaneous autoinjector in the U.S.

Outcome Details

FDA approved a once-daily subcutaneous autoinjector for self-administration of ZILBRYSQ in adults with gMG, adding a second self-administration option; described as the first and only macrocyclic peptide C5 inhibitor approved as a self-administered autoinjector in the U.S.

Importance:6/10

Sentiment:

0.50

FDA approvalautoinjectorself-administrationmyasthenia gravisC5 inhibitormacrocyclic peptidelabel expansion

Related Companies

$UCBJY

Read the original article

Published by PR Newswire Biotech on October 16, 2026 11:00 AM

Read Original